Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JNJ-42756493 dose regimens in FGFR-altered metastatic or unresectable urothelial cancer
2014-002408-26Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erdafitinib in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with best overall response. Started Mar 2015; status: active.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2014-002408-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002408-26.